Cargando…
Direct-Acting Antivirals Reduce the De Novo Development of Esophageal Varices in Patients with Hepatitis C Virus Related Liver Cirrhosis
The real-world benefits of direct-acting antiviral (DAA)-induced sustained virologic response (SVR) on the de novo occurrence and progression of esophageal varices (EV) remain unclear in patients with hepatitis C virus (HCV)-related liver cirrhosis (LC). This is a retrospective cohort study evaluati...
Autores principales: | Hsieh, Yung-Yu, Chen, Wei-Ming, Chang, Kao-Chi, Chang, Te-Sheng, Hung, Chao-Hung, Yang, Yao-Hsu, Tung, Shui-Yi, Wei, Kuo-Liang, Shen, Chen-Heng, Wu, Cheng-Shyong, Ding, Yuan-Jie, Hu, Jing-Hong, Huang, Yu-Ting, Lin, Meng-Hung, Lu, Chung-Kuang, Lin, Yi-Hsiung, Lin, Ming-Shyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860555/ https://www.ncbi.nlm.nih.gov/pubmed/36680293 http://dx.doi.org/10.3390/v15010252 |
Ejemplares similares
-
Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting
por: Lu, Yung-Hsin, et al.
Publicado: (2022) -
Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan
por: Huang, Yu-Ting, et al.
Publicado: (2021) -
Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan
por: Chang, Kao-Chi, et al.
Publicado: (2021) -
Fibrosis index predicts variceal bleeding and reduces need for nonselective beta-blocker in compensated cirrhosis with initial small esophageal varices without red-color sign
por: Wang, Sheng-Fu, et al.
Publicado: (2020) -
Selection of β‐Blocker in Patients With Cirrhosis and Acute Myocardial Infarction: A 13‐Year Nationwide Population‐Based Study in Asia
por: Wu, Victor Chien‐Chia, et al.
Publicado: (2018)